Risk stratification tools for heart failure in the diabetes clinic
The advent of Sodium Glucose Transporter 2-inhibitors (SGLT2-i) in recent years gave endocrinologists the opportunity to actively treat and prevent heart failure (HF) in patients with type 2 diabetes (T2DM). While the relationship between T2DM and HF has been extensively reviewed, previous work focused mostly on epidemiology, pathophysiology and treatment of HF in T2DM.The aim of our work was to aid health care professionals in identifying individuals at high risk for this dreadful complication.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Rosa Cannistraci, Simone Mazzetti, Andrea Mortara, Gianluca Perseghin, Stefano Ciardullo Tags: Viewpoint Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Epidemiology | Health Management | Heart | Heart Failure | Nutrition | SGLT2 Inhibitors | Sodium